SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, bUrRpPPP!, runncoach, kld2
Search This Board: 
Last Post: 8/23/2017 12:44:01 AM - Followers: 69 - Board type: Free - Posts Today: 1

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results 08/09/2017 08:30:00 AM
NTRP News: Quarterly Report (10-q) 08/08/2017 05:19:08 PM
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:36:00 AM
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:16:00 AM
NTRP News: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting 06/29/2017 09:30:00 AM
PostSubject
#4967  Sticky Note Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#4691  Sticky Note NEUROTROPE Announces Positive Top-Line Results From Phase 2 bUrRpPPP! 05/02/17 03:05:10 PM
#1870  Sticky Note NTRP has updated their Company presentation on their website: SF Wolf 03/14/17 08:33:06 AM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5377   Hope so as well. pennymonster1 08/23/17 12:44:00 AM
#5376   Hope so. Could use an update on runncoach 08/22/17 03:16:25 PM
#5375   Could be FragileX trial is getting close to announcement. Whatsupp 08/22/17 02:08:35 PM
#5374   Yes. Better volume since 3 pm yesterday though runncoach 08/22/17 01:27:45 PM
#5373   Volatile! on low volume. Any news good or Biostudent 08/22/17 01:03:37 PM
#5372   Nasdaq site scans 13-F SEC filings from major runncoach 08/16/17 04:35:25 PM
#5371   I am saying that some of their clients XenaLives 08/16/17 03:47:49 PM
#5370   Just go to the nasdaq site. Are you runncoach 08/16/17 11:48:09 AM
#5369   Their clients or the fund? XenaLives 08/16/17 10:32:43 AM
#5368   Read the filings. Black rock did buy in...and runncoach 08/16/17 09:38:46 AM
#5367   But they ain't no BlackRock XenaLives 08/16/17 09:15:40 AM
#5366   Lol. You claimed the 5% ownership last quarter runncoach 08/16/17 08:58:25 AM
#5365   So they can try to run it and XenaLives 08/16/17 08:48:14 AM
#5364   Interesting. Retailers sell and institutions will make the money runncoach 08/15/17 11:14:59 AM
#5363   Institutional holders up, to 12+% as of June Biostudent 08/15/17 09:55:25 AM
#5362   Almost nothing. Few hundred thousand a month runncoach 08/11/17 06:57:38 AM
#5361   What is cash burn? Thx pennymonster1 08/11/17 12:25:01 AM
#5360   Still 21 million cash on the books and runncoach 08/09/17 07:50:02 AM
#5359   Not sure there will be a conference call. runncoach 08/04/17 04:26:40 PM
#5358   What is their next news they can release? Biostudent 08/04/17 12:13:27 PM
#5357   Getting quiet here. nobrainerstocks 08/04/17 11:54:05 AM
#5356   Quarterly due in the next 2 weeks I runncoach 07/30/17 05:54:27 PM
#5355   Quarterly call Biostudent 07/30/17 02:28:08 PM
#5354   I covered my 23s @ 4.50 Bearly Bullish 07/28/17 07:08:32 PM
#5353   Hope so runncoach 07/28/17 05:26:41 PM
#5352   Stock is stabilized and climbing, and could go Maple tree 07/28/17 03:45:39 PM
#5351   Thanks F1ash. Good find. runncoach 07/27/17 06:50:44 AM
#5350   "2. All of the six key drugs F1ash 07/26/17 11:26:08 PM
#5349   Another positive news could be preclinical result of Maple tree 07/26/17 11:20:11 PM
#5348   Stick with your Neurotrope and lose all your nobrainerstocks 07/26/17 04:46:22 PM
#5347   Either news will be good and I would Maple tree 07/26/17 03:32:59 PM
#5346   I've got a stink bid in after seeing runncoach 07/26/17 03:25:49 PM
#5345   It seems people are in panic and I Maple tree 07/26/17 03:23:17 PM
#5344   We all know that 40ug will not be runncoach 07/25/17 08:29:20 PM
#5343   Treatment emergent adverse events of 64% in the Bearly Bullish 07/25/17 08:25:12 PM
#5342   The shorts campaign on this stock is so MaxTok 07/25/17 05:50:14 PM
#5341   But as Max also said it is irrelevant. Whatsupp 07/25/17 02:12:28 PM
#5340   Just passing along the conclusion from the study. runncoach 07/25/17 01:27:54 PM
#5339   Do you think people with epileptic seizures were runncoach 07/25/17 01:26:42 PM
#5338   Not true, sample size was not large enough, XenaLives 07/25/17 01:23:11 PM
#5337   No that's a new study showing that undetected XenaLives 07/25/17 01:21:03 PM
#5336   Was that the link to people already predisposed runncoach 07/25/17 01:13:26 PM
#5335   No because they weren't getting any free bryostatin runncoach 07/25/17 01:08:49 PM
#5334   Why did some of the patients not go XenaLives 07/25/17 01:05:55 PM
#5333   Nobody bought this stock due to Aegis and runncoach 07/25/17 09:54:20 AM
#5332   I wouldn't call March of this year "outdated" XenaLives 07/25/17 09:24:02 AM
#5331   Outdated and irrelevant MaxTok 07/25/17 08:55:38 AM
#5329   Aegis Capital - oops.... XenaLives 07/24/17 10:25:35 PM
#5328   Thank you for posting this. Biostudent 07/24/17 06:04:26 PM
#5327   I read it. Still have a buy runncoach 07/24/17 05:59:09 PM
PostSubject